First, genetic alterations in six cell lines were in line with literature data and furthermore, the BRAF mutation in WRO cells questions this cell line as a model for FTC, indeed this mutation does not occur in FTC. This evidence concerns the gene BRAF and thyroid cancer, nonmedullary, 2.